1-7 of 7
Jorge Romaguera, M.D
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Pentostatin, Cyclophosphamide, and Rituximab (PCR) Achieve High Response Rates in Indolent B-Cell Lyphoma without Prolonged Myelosuppression

Felipe Samaniego, M.D., Michelle Fanale, M.D., Barbara Pro, M.D., F.B. Hagemeister, M.D., Peter McLaughlin, M.D., Jorge Romaguera, M.D., Sattva Neelapu, M.D., Maria Alma Rodriguez, M.D., Luis Fayad, M.D., Anas Younes, M.D., Larry W. Kwak, M.D., Ph.D
Journal: Blood
Blood (2008) 112 (11): 835.
https://doi.org/10.1182/blood.V112.11.835.835
Published: 2008
Journal Articles

Results of Rituximab Plus ABVD in 65 Newly Diagnosed Patients with Classical Hodgkin Lymphoma: Improvement of Event Free Survival (EFS) in All International Prognostic Score (IPS) Groups.

Anas Younes, MD, Luis Y. Fayad, M.D., Andre Goy, M.D., Peter McLaughlin, M.D., Barbara Pro, M.D., Jorge Romaguera, M.D., Fredrick Hagemeister, M.D., Maria A. Rodriguez, M.D., Felipe Samaniego, M.D., Larry Kwak, M.D.Ph.D., Sattva Neelapu, M.D., L. Jeffrey Medeiros, M.D., Amanda Wedgwood, R.N., Michelle Fanale, M.D.
Journal: Blood
Blood (2006) 108 (11): 2742.
https://doi.org/10.1182/blood.V108.11.2742.2742
Published: 2006
Journal Articles

Sphingosomal Vincristine in CHOP +/− Rituximab Is a Promising New Treatment for Patients with High Risk Untreated Aggressive Non-Hodgkin’s Lymphoma (NHL): Follow-Up Results of a Phase II Study Sphingosomal Vincristine in CHOP +/− Rituximab Is a Promising New Treatment for Patients with High Risk Untreated Aggressive Non-Hodgkin’s Lymphoma (NHL): Follow-Up Results of a Phase II Study.

Maria Alma Rodriguez, M.D., Andreas Sarris, M.D., Nam H. Dang, M.D., Luis Fayad, M.D., Andre Goy, M.D., Fredrick Hagemeister, M.D., Peter McLaughlin, M.D., Barbara Pro, M.D., Jorge Romaguera, M.D., Felipe Samaniego, M.D., Anas Younes, M.D., Fernando Cabanillas, M.D.
Journal: Blood
Blood (2004) 104 (11): 4602.
https://doi.org/10.1182/blood.V104.11.4602.4602
Published: 2004
Journal Articles

Long-Term Safety and Efficacy of Single Administration of a Fixed Dose Pegfilgrastim (Neulasta) in Inducing Neutrophil Count Recovery after ABVD Chemotherapy in Patients with Hodgkin Lymphoma.

Anas Younes, M.D., Luis Fayad, M.D., Jorge Romaguera, M.D., Barbara Pro, M.D., Andre Goy, M.D., Nam Dang, M.D., Michael Wang, M.D.
Journal: Blood
Blood (2004) 104 (11): 4646.
https://doi.org/10.1182/blood.V104.11.4646.4646
Published: 2004
Journal Articles

A Phase II Study of Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) for Treatment of Patients with Relapsed and Refractory Mantle Cell Lymphoma (MCL).

Yasuhiro Oki, M.D., Barbara Pro, M.D., Ebrahim Delpassand, M. D., Verushka Ballaster, Peter McLaughlin, M.D., Jorge Romaguera, M.D., Michael Wang, M.D., Frederick B. Hagemeister, M.D., Anas Younes, M.D.
Journal: Blood
Blood (2004) 104 (11): 2632.
https://doi.org/10.1182/blood.V104.11.2632.2632
Published: 2004
Journal Articles

Safety and Efficacy of Bortezomib (Velcade) for the Treatment of Relapsed Classical Hodgkin’s Disease.

Anas Younes, M.D., Barbara Pro, M.D., Jorge Romaguera, M.D., Nam Dang, M.D.
Journal: Blood
Blood (2004) 104 (11): 2638.
https://doi.org/10.1182/blood.V104.11.2638.2638
Published: 2004
Journal Articles

Preliminary Results of a Phase I/II Trial of BBR-2778 (Pixantrone) in Combination with Fludarabine, Dexamethasone, and Rituximab (FPD-R) in the Treatment of Patients with Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma (NHL).

Luis Fayad, M.D, James Liebmann, M.D, Manuel Modiano, M.D, Gary I. Cohen, M.D, Barbara Pro, M.D, Jorge Romaguera, M.D, Cristina Davite, BSc, Margarita Lymboura, BSc, Silvia Comis, M.D, Bernard L. Laffranchi, M.D
Journal: Blood
Blood (2004) 104 (11): 1324.
https://doi.org/10.1182/blood.V104.11.1324.1324
Published: 2004